Enter your search

Celnova announces distribution agreement with Norgine

Celnova announces distribution agreement with Norgine

Celnova announces distribution agreement with Norgine

Celnova Pharma today announced that it has entered into an exclusive distribution agreement with SpePharm AG, a wholly owned subsidiary of Netherlands-based Norgine B.V., to commercialize DANTROLEN™ (dantrolene sodium) in the Argentine market.

Under the new agreement, Celnova Pharma will be responsible for marketing authorizations, market access, commercialization and distribution in Argentina.

“We are excited to be partnering with Norgine, a leading European specialist pharmaceutical company, in order to help expand the usage of DANTROLEN™ in Argentina” said Juan Marrone, CEO of Celnova Pharma.

“This agreement will assure an uninterrupted provision in Argentina of the only therapeutic option for patients suffering from malignant hyperthermia”.

About Norgine

Norgine is a leading European specialist pharmaceutical company with a direct commercial presence in all major European markets. In 2017, Norgine’s total revenue was EUR 345 million. Norgine employs over 1,000 people across its commercial, development and manufacturing operations and manages all aspects of product development, production, marketing, sale and supply.

Norgine specialises in gastroenterology, hepatology, cancer and supportive care.

Norgine is headquartered in the Netherlands. Norgine owns a R&D site in Hengoed, Wales and two manufacturing sites in Hengoed, Wales and Dreux, France. For more information, please visit www.norgine.com

In 2012, Norgine established a complementary business Norgine Ventures, supporting innovative healthcare companies through the provision of debt-like financing in Europe and the US. For more information, please visit www.norgineventures.com

NORGINE and the sail logo are trademarks of the Norgine group of companies.

About Celnova Pharma

Celnova Pharma is a pharmaceutical company focused in complex therapeutic classes, with a strong presence in oncology. Celnova’s business model combines proprietary branded generics with in-licensing of patent-protected and difficult-to-make generic drugs.

Celnova´s long term goal is to grow in Latin America through a mix of organic growth and selected acquisitions and partnerships. For more information, please visit www.celnova.com

Celnova Pharma is a registered trademark of Celnova Argentina S.A.